Streetbeat News

Products Services

CORZ

High-rolling investors have shown a bullish sentiment on Core Scientific (NASDAQ:CORZ) through significant options trading activity. Benzinga's options scanner identified 16 trades, with 75% being bullish. The price range of interest is between $9.5 and $14.5. Analysts have mixed ratings, with price targets ranging from $13 to $20.

Portfolio Pulse from Benzinga Insights

July 29, 2024 | 2:02 pm

TLRY

Tilray Brands, Inc. (NASDAQ:TLRY) announced that its subsidiary Aphria RX GmbH has received a trading license in Germany, allowing it to sell and distribute medical marijuana to pharmacies, hospitals, and medical wholesalers. This follows the recent acquisition of a cannabis cultivation license under Germany's new Cannabis Act, positioning Tilray to capitalize on the growing German market.

Portfolio Pulse from Jelena Martinovic

July 29, 2024 | 2:01 pm

USO

VGK

Russia's Deputy Prime Minister Novak announced that the Russian market is fully supplied with gasoline and diesel fuel.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:58 pm

SPY

USO

Russia's Novak announced that the domestic market is fully supplied with gasoline and diesel fuel.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:58 pm

A

Agilent Technologies has acquired Sigsense Technologies to enhance lab operations through AI and power monitoring. Financial terms were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:56 pm

AMZN

Amazon's Twitch faces profitability issues and slowed growth, raising concerns about its future. Despite generating significant revenue, Twitch remains unprofitable and has undergone multiple layoffs. Amazon's overall revenue expectations are also below consensus estimates.

Portfolio Pulse from Anusuya Lahiri

July 29, 2024 | 1:53 pm

PALI

Palisade Bio shares are trading higher after the company completed a microbiome study confirming bacterial enzymes for local bioactivation of PALI-2108.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:49 pm

LIPO

Lipella Pharmaceuticals shares are trading higher after the company announced it commenced its Phase 2a trial for LP-310 in Oral Lichen Planus.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:46 pm

VTYX

Ventyx Biosciences shares are trading lower after the company announced its Phase 2 trial of VTX958 for Crohn's disease did not meet its primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:46 pm

KD

VOD

Kyndryl and Vodafone Business have extended their partnership to enhance security and resiliency services for financial industry customers. The new agreement includes endpoint protection, vulnerability services, and web internet protection.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 1:43 pm